HTRA1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2171627	0.80	20/20
SCHEMBL2687419	0.59	16/20
SCHEMBL7402411	0.50	16/20
SCHEMBL5525443	0.49	14/20
Tasipeptin B (SCHEMBL1593428)	0.59	11/20
SCHEMBL7431656	0.39	11/20
SCHEMBL6210043	0.32	11/20
SCHEMBL6558805	0.47	10/20
Tasipeptin A (SCHEMBL1593407)	0.60	8/20
SCHEMBL6754840	0.57	8/20
SCHEMBL4403238	0.56	8/20
SCHEMBL1687874	0.55	8/20
SCHEMBL1687865	0.53	8/20
SCHEMBL860840	0.49	8/20
SCHEMBL6754841	0.47	8/20
SCHEMBL5742219	0.47	8/20
SCHEMBL5743477	0.44	8/20
Hydrochloric Acid (SCHEMBL5891471)	0.43	8/20
SCHEMBL4213137	0.43	8/20
SCHEMBL4213141	0.43	8/20

Clinical trials — most relevant to HTRA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency	PHASE4	ACTIVE_NOT_RECRUITING
Vorapaxar on Thrombin Generation and Coagulability	PHASE4	COMPLETED
Extending the Time for Thrombolysis in Emergency Neurological Deficits	PHASE3	COMPLETED
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment	PHASE3	NOT_YET_RECRUITING
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks	PHASE3	RECRUITING
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	PHASE3	COMPLETED
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.	PHASE1/PHASE2	COMPLETED
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery	PHASE1/PHASE2	UNKNOWN
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)	PHASE2	UNKNOWN
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32	PHASE2	COMPLETED
Interventional Management of Stroke (IMS) II Study	PHASE2	COMPLETED
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)	PHASE1/PHASE2	COMPLETED
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo	nan	RECRUITING
Genetic Architecture of Plasma T-PA and PAI-1	nan	COMPLETED
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Peri-implantitis and MMP-8	nan	COMPLETED
Surgical Revascularisation and Nerve Stimulation Trial	nan	WITHDRAWN
Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea	nan	COMPLETED
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease	nan	RECRUITING
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases	nan	COMPLETED
Thrombin Regulated Platelet Activation	nan	COMPLETED
Angioedema Biomarker Research Study	nan	UNKNOWN
Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry	nan	COMPLETED
Clinical and Genetic Analyzes of Age-related Macular Degeneration	nan	UNKNOWN
Hereditary Tubulointerstitial Nephritis	nan	COMPLETED
Gap Junction Potentiation of Endothelial Function With Rotigaptide	nan	COMPLETED
Identification and Characterization of Genetic Variants in Hereditary Angioedema	nan	NOT_YET_RECRUITING
Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HTRA1 binder may also engage these)

Protein	Name	Similarity
Q9QZK5	—	1.000	Q9QZK5 →
F1N152	—	1.000	F1N152 →
P83110	—	0.999	P83110 →
A4IHA1	—	0.997	A4IHA1 →
D3ZKF5	—	0.997	D3ZKF5 →
A6YFB5	—	0.996	A6YFB5 →
A2RT60	—	0.995	A2RT60 →
Q9D236	—	0.995	Q9D236 →
D3ZA76	—	0.994	D3ZA76 →
Q9R118	—	0.994	Q9R118 →
E1BJW1	—	0.989	E1BJW1 →
Q6GMI0	—	0.987	Q6GMI0 →
A9JRB3	—	0.986	A9JRB3 →
P83105	—	0.983	P83105 →
Q297U2	—	0.978	Q297U2 →
B3LVG7	—	0.977	B3LVG7 →
B4G316	—	0.977	B4G316 →
B4QZU6	—	0.977	B4QZU6 →
B3P3J9	—	0.976	B3P3J9 →
B4PST0	—	0.976	B4PST0 →
Q9VFJ3	—	0.975	Q9VFJ3 →
Q63415	—	0.975	Q63415 →
B4HEM8	—	0.975	B4HEM8 →
Q28193	—	0.975	Q28193 →
G4V4G1	—	0.975	G4V4G1 →
P54754	—	0.975	P54754 →
EPHB3	Ephrin type-B receptor 3	0.975	landscape →
B4K835	—	0.974	B4K835 →
O09127	—	0.974	O09127 →
EPHA5	Ephrin type-A receptor 5	0.974	landscape →